Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of June 2018. The registrant is a foreign private issuer based in Lausanne, Switzerland, focused on the development of treatments for neurodegenerative diseases. The filing primarily announces the submission of matters to a vote of security holders regarding the upcoming Annual General Meeting (AGM) scheduled for July 6, 2018.
Key Financial Metrics
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the period ending June 6, 2018. This document serves as a notice of shareholder meeting materials rather than a financial results report. Historical financial statements for the years ended December 31, 2017, 2016, and 2015 are referenced in the exhibit index but are not detailed within the body of this specific filing.
Material Changes
No material financial changes are reported in this document. The primary corporate action involves the Board of Directors proposing an extension of previous authorizations to raise capital. These authorizations, originally granted on April 27, 2018, are set to expire on July 27, 2018, and the proposal seeks to extend them until October 6, 2018.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. The primary risk and contingency noted is the requirement for shareholder approval to extend the capital raising authorization. Without this approval, the company's ability to raise capital under the previous mandate would cease on July 27, 2018.
Key Facts for Investor Verification
- AGM Date: The Annual General Meeting is scheduled for July 6, 2018.
- Record Date: Shareholders of record as of May 23, 2018, are eligible to vote.
- Capital Authorization: Shareholders are asked to vote on extending the capital raising authorization from July 27, 2018, to October 6, 2018.
- Financial Data Source: Current financial metrics are not in this text; investors must refer to the 2017 Statutory Financial Statements (Exhibit 99.4) or the 2017 Form 20-F (Exhibit 99.5) for the most recent audited data.